S100A4 oncoprotein plays a critical role during prostate cancer (CaP) progression and induces immunosuppression in host-tissues. We hypothesized that S100A4 activity in immunosuppressed prostate tumors promotes the growth of neoplastic cells which are likely to become aggressive.